European Journal of Pediatrics

, Volume 154, Issue 9, pp 700–707

Evaluation of low dose prostaglandin E1 treatment for ductus dependent congenital heart disease

  • Hans-Heiner Kramer
  • Michael Sommer
  • Spyros Rammos
  • Otto Krogmann
Original Paper Cardiology

DOI: 10.1007/BF02276712

Cite this article as:
Kramer, HH., Sommer, M., Rammos, S. et al. Eur J Pediatr (1995) 154: 700. doi:10.1007/BF02276712

Abstract

This study reports our experience with low-dose prostaglandin E1 (PGE1) treatment of 91 newborns with ductus dependent congenital heart disease (CHD). PGE1 efficacy, side-effects as well as the cardiovascular and respiratory profile of the patients were analysed. PGE1 doses > 0.02 μg/kg per minute were used for only 5.3% of the total 23 656 h of treatment. The mean systolic blood pressures did not differ from the normal mean for patients with cyanotic CHD, while the diastolic values were lowered. Respiratory support was required only during 13.7% of the total treatment time. Apnoeas occurred in 21 (38%) of the 55 spontaneously breathing infants, who all had a cyanotic CHD. The incidence of apnoeas was lower during treatment with doses < 0.01 μg/kg per minute.

Key words

Congenital heart disease Prostaglandin E1 Efficacy Side-effects Cardiovascular and respiratory profile 

Abbreviations

BAS

balloon atrial septostomy

CHD

congenital heart disease

PGE1

prostaglandin E1

SD

standard deviation

SO2

oxygen saturation

Copyright information

© Springer-Verlag 1995

Authors and Affiliations

  • Hans-Heiner Kramer
    • 1
  • Michael Sommer
    • 1
  • Spyros Rammos
    • 1
  • Otto Krogmann
    • 1
  1. 1.Department of Paediatric Cardiology, Children's HospitalHeinrich-Heine-UniversityDüsseldorfGermany
  2. 2.Clinic for Paediatric CardiologyChristian-Albrechts-UniversityKiel 1Germany

Personalised recommendations